〔Abstract〕Objective To explore the clinical value of recombinant human interferon combined with routine triple atomization in the treatment of infantile viral pneumonia. Methods A total of 60 children with viral pneumonia admitted to Guangzhou Baiyun District Maternity and Child Health Care Hospital from January 2018 to January 2020 were selected as the research objects, and they were randomly divided into a control group and an observation group. The 30 cases in the control group according to the random number table method, were given basic treatment combined with routine triple atomization; the 30 cases in the observation group were given the compressed atomization inhalation of recombinant human interferon on the basis of the control group. The clinical symptom regression time, serum inflammatory indexes (tumor necrosis factor - α, interleukin-6, interleukin-8) before and after treatment, as well as clinical efficacy and adverse reactions of the two groups were compared. Results The times of cough, wheezer, fever and pulmonary rales subsided in the observation group were shorter than those in the control group, the clinical cure rate was higher than that in the control group, and the levels of serum inflammatory indexes after treatment were lower than those in the control group, the differences were statistically significant (P < 0.05). No adverse reactions were observed in the two groups during treatment. Conclusion Recombinant human interferon combined with routine triple nebulization in the treatment of infantile viral pneumonia can accelerate the subsidence of clinical symptoms in children and better improve the inflammatory response.The effect is superior to simple triple atomization and has high safety